TrialGenome medicine2022

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.

Jung Yong Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.